



# TECHNOLOGY EVALUATION CONSORTIUM™

Quantitative Medicine Meeting with Abbvie  
Wednesday, August 14, 2013  
Webinar

## **Cambridge Healthtech Associates**

Dawn Van Dam (General Manager)  
Amid Zand (Project Manager)  
Ernie Bush (Scientific Director)

### **Quantitative Medicine**

John King  
Scott Bodine  
Geoff Hoare  
Joshua Kangas  
David Demosthenes  
*Jim Parrino (not on call)*  
*Bob Murphy (not on call)*  
*Jamie Grooms (not on call)*

**Abbvie**  
Eric Blomme

## **Agenda**

- I) Opening Remarks: CHA – Ernie, Dawn
- II) One on One Discussion: Quantitative Medicine Slides
- III) Closing and Action Items

## I) Opening Remarks

Ernie briefly introduced Quantitative Medicine and welcomed Eric Blomme of Abbvie.

Eric introduced himself and explained his role at Abbvie. He explained his involvement with three groups: safety pharmacology, discovery toxicology, and investigative toxicology pathology. He is heavily involved with early drug discovery.

Eric expressed interest in the Quantitative Medicine approach as he believes Abbvie has a similar platform currently in place.

---

## II) One on One Discussion: Quantitative Medicine's Presentation

John King of Quantitative Medicine welcomed Eric and introduced himself and the members of Quantitative Medicine participating in the meeting. John turned the meeting over to Joshua Kangas.

Josh expressed specific interest in how the Quantitative Medicine system compares to the platform currently in place at Abbvie.

Josh presented Quantitative Medicine's slides intended to cover several major topics:

1. Comparison with Current Experimental Approaches
2. AFRS Use Cases: Situation, Action, Results

Eric expressed a desire for a more concrete, practical example. He further explained that the potential value in a system would be in more efficient synthesis of new compounds.

Eric explained that he would like to see Quantitative Medicine concretely show how their system would create a more accurate predictive model.

Ernie pointed out that Eric was highlighting the major difference between previous projects and the one at hand: the Quantitative Medicine system is not a finished tool that has produced results that can be clearly shown. Quantitative Medicine is looking for an individual willing to try the system and possibly demonstrate its 'real world' utility.

John asked Eric what machine learning tools are currently in use at Abbvie and in what research areas they are active.

Eric explained that there are many tools in place. They are being used to identify off target effects and evaluate transcriptomic data.

Josh explained, in a bit more detail, the type of experimental space for which the Quantitative Medicine AFRS system is best suited and asked Eric if he had any thoughts on a way this approach could be extended into a project which would demonstrate for him, in a more relevant way, its effectiveness.

---

### III) Closing Remarks and Action Items

Eric asked if a potential project would be addressed through the consortium.

Ernie explained that because of initial concerns about data sharing between members, one on one projects are currently being considered. Ernie suggested use of the companies' large repositories of off target screening data.

**Eric:** I think I would need to internally discuss this system with concept experts and evaluate their interest. If there is interest I can link the Quantitative Medicine team with the appropriate people within Abbvie.

Additionally, Eric suggested he first speak to the appropriate parties and if there is interest he would like to set up a phone call between those individuals and Quantitative Medicine.

Dawn relayed that CHA would be happy to listen in to any such communication to support the continuity of the process.

John explained that Quantitative Medicine will provide information as the process proceeds per Eric's request.

Contact information was to be exchanged between Quantitative Medicine and Eric Blomme of Abbvie.